BASEL, Switzerland, Sept. 6, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced upcoming presentations by David Hung, M.D., chief executive officer of Axovant, on September 6, 2017 at 12:50 p.m. ET at the Baird 2017 Global Healthcare Conference, and on September 12, 2017 at 10:35 a.m. ET at the Morgan Stanley Global Healthcare Conference.
A simultaneous webcast will be available for each conference in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following each conference.
About Axovant Sciences
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant has a pipeline of late- and early-stage product candidates that focuses on the cognitive, functional, and behavioral aspects of debilitating conditions such as Alzheimer's disease and Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.
Contacts:
Investors
Jonathan Neely
jonathan.neely@axovant.com
Media
Samina Bari
samina.bari@axovant.com
SOURCE Axovant Sciences Ltd.